Single and Multiple Ascending Dose Study of AER-01

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, Phase 1 study of AER-01 (solution for inhalation, delivered via nebulizer) to assess the safety, tolerability and PK of AER-01. The study will be conducted in 2 parts: a single ascending dose (SAD) part in HVs (Part A) and a 7-day multiple ascending dose (MAD) part in HVs(Part B).

Timeline

Start

2023-05-26

Primary completion

2024-08

Completion

2024-08

Drugs

Indications